Compare Kinross Gold Corporation (KGC) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinross Gold Corporation vs Regeneron Pharmaceuticals Inc — how do they compare? Kinross Gold Corporation trades at $27.64 (market cap $32.29B), while Regeneron Pharmaceuticals Inc trades at $797.49 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.5× Kinross Gold Corporation's market cap, and Kinross Gold Corporation pays the higher dividend (0.59%). Which is the better fit depends on your goals.
| KGC | REGN | |
|---|---|---|
Market Cap | $32.29B | $82.06B |
Sector | Basic Materials | Health |
52-Week High | $38.06 | $812.27 |
52-Week Low | $18.70 | $555.51 |
Enterprise Value | $30.37B | $76.77B |
Dividend Yield | 0.59% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinross Gold (KGC) trades at $27.70, up 1.09% today, with a bullish technical signal from moving averages but overbought RSI levels. The company demonstrates robust fundamentals, with Q2 2026 EPS beating estimates at $0.71 versus $0.66 expected, and strong cash flow growth, with 2025 operating cash flow at $3.76 billion. Recent news includes a credit rating upgrade to 'BBB' by S&P Global Ratings on August 6, 2026, and ongoing project developments like Lobo-Marte.
The outlook is positive, supported by earnings beats, rising gold prices, and a consensus price target of $37.20, implying 34% upside. Risks include cost pressures and gold price volatility, but institutional buying and a 58.6% analyst buy rating suggest confidence in continued growth.
Regeneron Pharmaceuticals (REGN) trades at $794.71, down 1.65% on the day, with strong fundamentals including a P/E of 19.72 and net income margin of 27.86%. The stock is in a bullish technical trend, supported by moving averages, though RSI levels indicate overbought conditions. Recent quarterly EPS results have consistently beaten expectations, and the company maintains robust cash flow from operations of $4.98 billion in 2025. However, multiple class action lawsuits related to clinical trial disclosures present a near-term headwind.
The outlook remains positive due to earnings strength and analyst consensus, but legal risks and high valuation multiples warrant caution. Upside is supported by product growth in Eylea HD and Dupixent, while downside risks include litigation outcomes and potential regulatory scrutiny. The stock trades above the consensus price target of $756.93, suggesting limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
